ClinicalTrials.gg
CompletedNCT03362853Updated Dec 6, 2017

A Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects and the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics

A Phase 1 interventional study of Nemonoxacin 500Mg Capsule and Moxifloxacin 400Mg Tablet in Healthy Volunteers, sponsored by TaiGen Biotechnology Co., Ltd.. Completed. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-06.

Sponsored by TaiGen Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 years 4 months after the study started (first participant enrolled Jun 2012, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

A randomized, single-center, placebo and positive control, 4-period and 4-crossover clinical study with the following main purposes: (1) To evaluate the effect of a single-dose oral administration of nemonoxacin malate capsule on QTc intervals and heart rhythms of healthy subjects. (2) To evaluate the influence of food intake on QTc intervals and pharmacokinetic characteristics.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

TaiGen Biotechnology Co., Ltd. is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged between 18 and 40 during the screening period.
  2. A volunteer's (BMI) had to be between 19\~24 kg/m2, and a male volunteer's body weight was no less than 50 kg, while female, no less than 45 kg.
  3. A subject was judged as a healthy one by investigators according to his/her medical history, physical examination, 12-lead examination, and laboratory test results.
  4. A female subject:

    1. was for at least 1 year, or
    2. had been surgically sterilized, or
    3. met the following conditions if she was fertile: (i)her urine pregnancy test results were negative before she started the trial, and (ii)she agreed to use an approved method (e.g. oral contraceptive, spermicide, condom, or intrauterine contraceptive device) throughout the study, and agreed to continue using birth control method within 1 month after the study, and (iii)she may not breastfeed.
  5. A male subject had to use a reliable birth control method (using a condom, or his partner executed the foresaid criteria) throughout the study and within 1 month after the study.
  6. A subject had never used tobacco or nicotine products within 1 month before receiving the study drug.
  7. A subject had never drunk alcohol or drunk more than 12 times within 3 months before receiving the study drug.
  8. A subject was willing to completely abstain from foods or beverages containing caffeine or xanthine such as coffee, tea, chocolate, alcohol, grapefruit juice, orange juice, etc within 24 hours before receiving the study drug and during his/her Stage I ward stay.
  9. A subject was willing to sign the Form.

Exclusion criteria

Exclusion Criteria:

  1. had any personal or family history of sudden cardiac death, myocardial ischemia, myocardial infarction, congestive heart failure, long syndrome, hypokalemia, myocarditis, exertional dyspnea, cerebrovascular accident, venous thromboembolism, etc; or
  2. needed to use medicine to treat QTc interval prolongation (e.g. Category I or III antiarrhythmic drugs, please refer to Appendix 1) or medicine to treat heart disease; or
  3. was found to have abnormal mean values of parameters in 12-lead during the screening: PR >240 ms, QRS >110 ms, male QTcF >430 ms (the automated machine-derived QTcF results in Lead II ECG were used and needed to be confirmed by the investigators), female QTcF >450 ms (the automated machine-derived QTcF results in Lead II ECG were used and needed to be confirmed by the investigators), bradycardia (heart rate \<50 bpm); or
  4. had clinical abnormalities in 12-lead ECG during screening (e.g. atrioventricular block, torsades de pointes (TdP), other types of ventricular tachycardia, ventricular fibrillation and ventricular flutter, T wave changes, or any 12-lead ECG abnormalities that may influence QTc intervals); or
  5. had systolic blood pressure >140 mmHg or \<90 mmHg, diastolic blood pressure >90 mmHg, pulse \<50 bpm or >100 bpm during the screening; or
  6. had a positive result in virus or virus serology test; or
  7. had a positive pregnancy test result or was currently in lactation period; or
  8. was found to have any laboratory test value that was outside the reference value (normal value±10%) during the screening, and that was deemed to have clinical significance by investigators; or
  9. had a history of diabetes or cardiovascular disease, liver disease or kidney disease; or
  10. had malabsorption syndrome or any other gastrointestinal disease that may influence drug absorption; or
  11. had any history of epileptic seizures, or mental disease that may affect protocol compliance, or had a suicidal risk, or had history of alcohol or prohibited drug abuse; or
  12. had any disease known to severely affect the immune system, e.g. history of (HIV) infection, hematologic or solid organ , or had a splenectomy, etc; or
  13. had a hypersensitive idiosyncrasy or to any drugs, including quinolones or fluoroquinolones; or
  14. had a surgery or trauma history within 6 months before receiving the study drug; or
  15. had, as shown from his/her medical history, used any known liver enzyme inducer or liver enzyme inhibitor such as benzedrine, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, phencyclidine, etc within 30 days before receiving the study drug; or
  16. had used any other trial drugs within 30 days before receiving the study drug; or
  17. had used any prescription drugs or Chinese herbal medicines within 14 days before receiving the study drug; or
  18. had used any OTC drugs or nutrition supplements (including the products containing multivalent cation such as calcium, aluminum, magnesium, iron, and zinc, as well as sucralfate, antacids, nutrition supplements, vitamin complex, and dietary metal supplements, etc) within 7 days before receiving the study drug; or
  19. had donated ≥400 ml of blood within 3 months before drug administration; or
  20. had, as judged by the investigators, any past or current disease or physical condition that may affect the safety or effect evaluation of the study drug; or
  21. was identified by the investigators as unsuitable to participate in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Nemonoxacin 500Mg Capsule

    Drug: Nemonoxacin 500Mg Capsule · Drug: Moxifloxacin 400Mg Tablet · Drug: Nemonoxacin 750Mg Capsule · Drug: Placebo oral capsule

  • Experimental
    Nemonoxacin 750Mg Capsule

    Drug: Nemonoxacin 500Mg Capsule · Drug: Moxifloxacin 400Mg Tablet · Drug: Nemonoxacin 750Mg Capsule · Drug: Placebo oral capsule

  • Placebo comparator
    Placebo oral capsule

    Drug: Nemonoxacin 500Mg Capsule · Drug: Moxifloxacin 400Mg Tablet · Drug: Nemonoxacin 750Mg Capsule · Drug: Placebo oral capsule

  • Active comparator
    Moxifloxacin 400Mg Tablet

    Drug: Nemonoxacin 500Mg Capsule · Drug: Moxifloxacin 400Mg Tablet · Drug: Nemonoxacin 750Mg Capsule · Drug: Placebo oral capsule

Interventions

06

What researchers measure

Primary outcomes

  1. ECG analysis - baseline-adjusted mean QTcF

    To compare the post-dosing placebo-corrected, baseline-adjusted mean QTcF differences (ΔΔQTcF) of nemonoxacin 500 mg/750 mg groups and placebo group at corresponding time points with the manually measured QTcF in Lead II of ECG.

    Time frame: 2 days

Secondary outcomes

  1. ECG analysis - baseline-adjusted mean QTcB

    To compare the post-dosing placebo-corrected, baseline-adjusted mean QTcB differences (ΔΔQTcF) of nemonoxacin 500 mg/750 mg groups and placebo group at corresponding time points with the manually measured QTcB in Lead II of ECG.

    Time frame: 2 days

  2. ECG analysis - baseline-adjusted mean QTcP

    To compare the post-dosing placebo-corrected, baseline-adjusted mean QTcP differences (ΔΔQTcF) of nemonoxacin 500 mg/750 mg groups and placebo group at corresponding time points with the manually measured QTcP in Lead II of ECG.

    Time frame: 2 days

  3. Safety analysis

    An analysis of adverse event (number and percentage of subjects) was conducted based on dosage groups

    Time frame: 33 days

  4. Maximum Plasma Concentration (Cmax)

    The analysis was conducted using the well-validated software (WinNolin and DAS programs). A non-compartment model was used to analyze the plasma concentration-time data of nemonoxacin and moxifloxacin, thus the pharmacokinetic parameter was evaluated, and a descriptive summary of the plasma concentration-time data by dosage groups and time points were presented. Also, a descriptive summary of pharmacokinetic parameters were made based on dosage groups.

    Time frame: 2 day

  5. Time at Which Maximum Plasma Concentration was Observed (Tmax)

    The analysis was conducted using the well-validated software (WinNolin and DAS programs). A non-compartment model was used to analyze the plasma concentration-time data of nemonoxacin and moxifloxacin, thus the pharmacokinetic parameter was evaluated, and a descriptive summary of the plasma concentration-time data by dosage groups and time points were presented. Also, a descriptive summary of pharmacokinetic parameters were made based on dosage groups.

    Time frame: 2 day

  6. Area Under the Plasma Concentration-Time Curve Calculated to the Last Measured Concentration (AUC(0~t))

    The analysis was conducted using the well-validated software (WinNolin and DAS programs). A non-compartment model was used to analyze the plasma concentration-time data of nemonoxacin and moxifloxacin, thus the pharmacokinetic parameter was evaluated, and a descriptive summary of the plasma concentration-time data by dosage groups and time points were presented. Also, a descriptive summary of pharmacokinetic parameters were made based on dosage groups.

    Time frame: 2 day

  7. Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC(0~∞))

    The analysis was conducted using the well-validated software (WinNolin and DAS programs). A non-compartment model was used to analyze the plasma concentration-time data of nemonoxacin and moxifloxacin, thus the pharmacokinetic parameter was evaluated, and a descriptive summary of the plasma concentration-time data by dosage groups and time points were presented. Also, a descriptive summary of pharmacokinetic parameters were made based on dosage groups.

    Time frame: 2 day

  8. Lambda-z (λz)

    The analysis was conducted using the well-validated software (WinNolin and DAS programs). A non-compartment model was used to analyze the plasma concentration-time data of nemonoxacin and moxifloxacin, thus the pharmacokinetic parameter was evaluated, and a descriptive summary of the plasma concentration-time data by dosage groups and time points were presented. Also, a descriptive summary of pharmacokinetic parameters were made based on dosage groups.

    Time frame: 2 day

  9. half-life (t1/2)

    The analysis was conducted using the well-validated software (WinNolin and DAS programs). A non-compartment model was used to analyze the plasma concentration-time data of nemonoxacin and moxifloxacin, thus the pharmacokinetic parameter was evaluated, and a descriptive summary of the plasma concentration-time data by dosage groups and time points were presented. Also, a descriptive summary of pharmacokinetic parameters were made based on dosage groups.

    Time frame: 2 day

  10. Oral Clearance (CLt/F)

    The analysis was conducted using the well-validated software (WinNolin and DAS programs). A non-compartment model was used to analyze the plasma concentration-time data of nemonoxacin and moxifloxacin, thus the pharmacokinetic parameter was evaluated, and a descriptive summary of the plasma concentration-time data by dosage groups and time points were presented. Also, a descriptive summary of pharmacokinetic parameters were made based on dosage groups.

    Time frame: 2 day

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Zhao C, Lv Y, Li X, Hou F, Ma X, Wei M, Kang Z, Cui L, Xia Y, Liu Y, Tian J. Effects of Nemonoxacin on Thorough ECG QT/QTc Interval: A Randomized, Placebo- and Positive-controlled Crossover Study in Healthy Chinese Adults. Clin Ther. 2018 Jun;40(6):983-992. doi: 10.1016/j.clinthera.2018.04.014. Epub 2018 May 24. PubMed 29803534 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2012 to primary completion in Aug 2012, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2017
First posted
Dec 5, 2017
StartActual
Jun 25, 2012
Primary completionActual
Aug 10, 2012
CompletionActual
Aug 10, 2012
Last update
Dec 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03362853
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Dec 5, 2017
Start date
Jun 25, 2012
Primary completion
Aug 10, 2012
Completion
Aug 10, 2012
Last update
Dec 6, 2017

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemonoxacin

Start the discussion